Market research
BBI Brickell Biotech Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 17.83
- Dividend yield
- 0.0%
- Beta
- 0.08
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- US10802T1051
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 17.83
- Dividend yield
- 0.0%
- Beta
- 0.08
About
About Brickell Biotech Inc
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BBI discussion.
5 years, 4 months ago
Brickell Biotech, Inc is currently in a long term downtrend where the price is trading 13.8% below its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.2.
Brickell Biotech, Inc's total revenue sank by 96.0% to $27K since the same quarter in the previous year.
Its net income has increased by 32.2% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 66.2% to $-5M since the same quarter in the previous year.
Based on the above factors, Brickell Biotech, Inc gets an overall score of 3/5.